Profile data is unavailable for this security.
About the company
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
- Revenue in CHF (TTM)1.29bn
- Net income in CHF154.39m
- Incorporated1904
- Employees3.93k
- LocationSiegfried Holding AGUntere Bruehlstrasse 4ZOFINGEN 4800SwitzerlandCHE
- Phone+41 627461111
- Fax+41 627461202
- Websitehttps://www.siegfried.ch/
More ▼
Mergers & acquisitions
| Acquired company | SFZN:SWX since announced | Transaction value |
|---|---|---|
| Noramco Inc,Purisys LLC | 1.48% | -- |
| Tasmanian Alkaloids Pty Ltd | 1.48% | -- |
Data delayed at least 15 minutes, as of Feb 16 2026 16:31 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 322.20m | 86.55m | 3.73bn | 3.11k | 43.05 | -- | 40.36 | 11.56 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 152.24m | 96.71m | 4.04bn | 995.00 | 41.95 | 6.15 | -- | 26.53 | 1.40 | 1.40 | 2.21 | 9.56 | 0.186 | 1.54 | 4.55 | 1,377,045.00 | 11.66 | 3.14 | 15.35 | 3.34 | 74.88 | 77.37 | 62.65 | 16.95 | 1.97 | -- | 0.00 | 12.57 | 17.70 | 0.2733 | 139.15 | 25.17 | 16.61 | -- |
| Mirum Pharmaceuticals Inc | 362.17m | -31.80m | 4.09bn | 355.00 | -- | 18.12 | -- | 11.29 | -0.8613 | -0.8613 | 9.26 | 5.69 | 0.6494 | 4.15 | 5.37 | 1,465,199.00 | -5.70 | -29.54 | -7.04 | -34.57 | 79.92 | -- | -8.78 | -92.71 | 3.16 | -22.48 | 0.5144 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
| Siegfried Holding AG | 1.29bn | 154.39m | 4.12bn | 3.93k | 25.94 | 3.90 | 17.18 | 3.19 | 3.52 | 3.52 | 29.45 | 23.37 | 0.6724 | 2.05 | 3.67 | 333,038.10 | 8.02 | 7.21 | 9.74 | 8.83 | 25.69 | 24.10 | 11.92 | 10.20 | 1.45 | 14.96 | 0.3127 | 13.14 | 1.82 | 9.21 | 42.46 | 28.12 | 23.91 | 6.30 |
| PTC Therapeutics, Inc. | 1.37bn | 577.06m | 4.28bn | 939.00 | 8.14 | -- | 7.11 | 3.13 | 8.53 | 8.53 | 21.64 | -1.95 | 0.7932 | 1.28 | 8.83 | 1,894,728.00 | 33.51 | -26.68 | 49.97 | -34.84 | 96.83 | 93.49 | 42.25 | -74.67 | 2.26 | 6.03 | 1.07 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Gan & Lee Pharmaceuticals | 427.50m | 102.86m | 4.31bn | 5.25k | 41.45 | 3.44 | -- | 10.09 | 1.57 | 1.57 | 6.54 | 18.88 | 0.3158 | 0.9071 | 9.73 | 733,533.10 | 7.60 | 6.19 | 8.10 | 6.58 | 74.62 | 81.80 | 24.06 | 22.31 | 5.57 | -- | 0.001 | 44.12 | 16.77 | 1.02 | 80.75 | -12.04 | 1.63 | -- |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 8.62bn | 331.85m | 4.34bn | 28.14k | 13.67 | 1.08 | -- | 0.5034 | 1.84 | 1.84 | 47.69 | 23.32 | 0.9548 | 5.79 | 4.33 | 2,755,662.00 | 3.83 | 5.33 | 7.36 | 10.95 | 16.23 | 18.07 | 4.01 | 5.28 | 1.31 | -- | 0.2873 | 28.87 | -0.692 | 2.92 | -30.09 | -2.32 | -14.01 | 6.32 |
Data as of Feb 16 2026. Currency figures normalised to Siegfried Holding AG's reporting currency: Swiss Franc CHF
21.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Z�rcher Kantonalbank (Investment Management)as of 22 Oct 2025 | 2.26m | 5.01% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.61m | 3.55% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.36m | 3.00% |
| UBS Asset Management Switzerland AGas of 14 Aug 2025 | 1.30m | 2.87% |
| BlackRock Fund Advisorsas of 17 Sep 2025 | 1.23m | 2.73% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 777.94k | 1.72% |
| Vontobel Asset Management AGas of 31 Jan 2026 | 383.43k | 0.85% |
| DWS Investment GmbHas of 05 Feb 2026 | 353.79k | 0.78% |
| AXA Investment Managers (Paris) SAas of 30 Dec 2025 | 259.89k | 0.58% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 215.01k | 0.48% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
